195
Views
0
CrossRef citations to date
0
Altmetric
Articles

Nonerosive reflux disease as a presentation of gastro-oesophageal reflux disease

, MMed (Internal Medicine) (Gastroenterology Fellow)
Pages 326-331 | Received 05 Apr 2011, Accepted 21 May 2011, Published online: 15 Aug 2014

References

  • Fabio P, Valentina C, Stefano P. Heterogeneity of endoscopy negative heartburn: epidemiology and natural history. World J Gastroenterol. 2008; 14(20): 3123–3128.
  • Tiberiu H, Ronnie F. Nonerosive reflux disease (NERD)—an update. J Neurogastroenterol Motil. 2010; 16(1): 8–21.
  • Quigley EMM. New developments in the pathophysiology of gastro-oesophageal reflux disease (GORD): implications for patient management. Aliment Pharmacol Ther. 2003; 17: 43–51.
  • Fass R, Naliboff B, Higa L, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity. Gastroenterology 1998; 115: 1363–1373.
  • Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995; 37: 7–12.
  • Drossman DA. Importance of the psyche in heartburn and dyspepsia. Aliment Pharmacol Ther. 1997; 11: 57–67.
  • Johnston BT, Lewis SA, Collins JSA, et al. Acid perception in gastro-oesophageal reflux disease is dependent on psychological factors. Scand J Gastroenterol. 1997; 32: 974–9.
  • Kahrilas PJ, Dodds WJ, Hogan WJ, et al. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology 1986; 91: 897–904.
  • Martinez SD, Malagon IB, Garewal HS, et al. Nonerosive reflux disease (NERD)—acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003; 17: 537–545.
  • Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol. 1999; 94: 2054–2059.
  • Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998; 10: 119–124.
  • Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily omeprazole 20 milligrams once daily or ranitidine 150 milligrams twice daily evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997; 32: 965–973.
  • Barlow WJ, Orlando RC. Review: the pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005; 128: 771–778.
  • DeVault KR, Castell DO, and the Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 1999; 94: 1434–1442 Inflammatory disorders of the esophagus: reflux and nonreflux types. In: Lewin KJ, Riddell RH, Weinstein WM, editors. Gastrointestinal pathology and its clinical implications. New York: Igaku-Shoin, 1992: 401–439.
  • Fauci AS, Braunwald E, Kasper DL, et al. Harrison's principles of internal medicine. 17th edition. New York: McGraw-Hill Professional, 2008; p. 1851–1852.
  • Kahrilas PJ, Quigley EMM. American Gastrointestinal Association medical position statement: guidelines on the use of esophageal pH recording. Gastroenterology 1996; 110: 1981–1996.
  • Funch-Jensen P, Kock K, Christensen LA, et al. Microscopic appearance of the esophageal mucosa in a consecutive series of patients submitted to upper endoscopy. Correlation with gastroesophageal reflux symptoms and macroscopic findings. Scand J Gastroenterol. 1986; 21: 65–69.
  • Schindlbeck NE, Weibecke B, Klauser AG, et al. Diagnostic value of histology in non-erosive gastro-oesophageal reflux disease. Gut 1996; 39: 151–154.
  • Chey WD. Editorial: Erosive esophagitis and NERD: can we really classify patients with heartburn by endoscopic findings? Clin Gastroenterol Hepatol. 2004; 2: 654–655.
  • Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled randomized trial. Aliment Pharmacol Ther. 1999; 13: 907–914.
  • Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997; 32: 974–979.
  • Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole the treatment of patients with reflux symptoms and physiological levels of acid reflux—the “sensitive esophagus”. Gut 1997; 40: 587–590.
  • Fass R, Ofman JJ, Sampliner RE, et al. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive esophagitis. Aliment Pharmacol Ther. 2000; 14: 389–396.
  • Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol. 1997; 92: 1997–2000.
  • Ofman JJ, Gralnek IM, Udani J, et al. The cost-effectiveness of the omeprazole test in non-cardiac chest pain. Am J Med 1999; 107: 219–227.
  • Schindlbeck NE, Klauser AG, Voderholzer WA, Müller-Lissner SA. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med. 1995; 155: 1808–1812.
  • Fenton P, Terry ML, Galloway KD, et al., Is there a role for laparoscopic fundoplication in patients with non-erosive reflux disease (NERD)? Gastroenterology, 2000; 118(Suppl. 2): A481.